Context Therapeutics Approves Reverse Stock Split Amendment

Context Therapeutics ( (CNTX) ) has shared an update.

On June 12, 2025, Context Therapeutics Inc. held its Annual Meeting of Stockholders, where two key proposals were voted on. Stockholders ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for 2025. Additionally, an amendment for a reverse stock split of the company’s common stock was approved, allowing the Board of Directors to determine a split ratio between 1-for-5 and 1-for-50. These decisions could impact the company’s financial structure and market positioning.

The most recent analyst rating on (CNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.

Spark’s Take on CNTX Stock

According to Spark, TipRanks’ AI Analyst, CNTX is a Underperform.

Context Therapeutics has significant financial challenges, with no revenue and consistent losses, heavily weighing down its overall score. Technical analysis shows neutral market momentum, while valuation metrics highlight unprofitability. However, the recent initiation of a Phase 1 trial offers some hope for future growth. Collectively, these factors result in a low overall stock score, reflecting the company’s current financial instability and speculative potential.

To see Spark’s full report on CNTX stock, click here.

More about Context Therapeutics

Context Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the development of therapies for hormone-driven cancers. The company is engaged in advancing its pipeline of innovative treatments to address unmet medical needs in oncology.

Average Trading Volume: 230,232

Technical Sentiment Signal: Sell

Current Market Cap: $59.97M

See more insights into CNTX stock on TipRanks’ Stock Analysis page.